Cellectis SA (CMVLF)
OTHER OTC:CMVLF
Want to see CMVLF full AI Analyst Report?
CMVLF Stock Chart & Stats
$4.40
-$0.25(-16.67%)
At close: 4:00 PM EST
$4.40
-$0.25(-16.67%)
Day’s Range― - ―
52-Week Range$1.25 - $5.04
Previous CloseN/A
Volume1.60K
Average Volume (3M)6.00
Market Cap
$294.19M
Enterprise Value$328.22M
Total Cash (Recent Filing)$208.69M
Total Debt (Recent Filing)$119.91M
Price to Earnings (P/E)―
Beta-0.37
Next Earnings
Apr 30, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding72,325,455
10 Day Avg. Volume20
30 Day Avg. Volume6
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)6.52
Price to Sales (P/S)6.52
P/FCF Ratio-11.22
Enterprise Value/Market Cap1.12
Enterprise Value/Revenue4.49
Enterprise Value/Gross Profit5.37
Enterprise Value/Ebitda-9.62
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.1
Revenue Forecast (FY)$62.03M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & Gross MarginA strong top-line rebound with a ~72% gross margin in 2025 indicates the company's platform and partner-driven model can generate high-margin revenue. That structural margin profile helps fund R&D and partnerships over the next several quarters despite operating losses.
Milestone & Royalty Potential From LicensingThe Servier/Allogene sublicensing pathway offers material milestone and royalty upside tied to cema-cel development and potential commercialization. These contingent payments are a durable non-dilutive funding source if clinical progress continues and can materially de-risk financing needs.
Proprietary Allogeneic Gene‑editing PlatformCellectis' focus on off-the-shelf, gene-edited CAR-Ts is a structural competitive advantage versus autologous approaches: potential for scalable manufacturing, lower per-patient cost and easier deployability, which supports long-term partner interest and commercial scalability.
Bears Say
Persistent Deep LossesOperating and net losses of this magnitude show the business is not yet profitable and losses are structurally large versus revenue. Persistent negative earnings reduce retained capital, pressure equity, and increase reliance on external funding or partner milestone timing to sustain operations.
Negative Cash GenerationCash flow swung from positive in 2024 to sharply negative in 2025, reflecting renewed cash burn. This reversal materially raises financing risk over the medium term, increasing probability of capital raises or accelerated partner-deal dependence to maintain R&D and trial timelines.
Rising Leverage / Weaker Balance SheetDebt roughly 1.6x equity (up from ~0.7x) signals a meaningful increase in leverage. Higher debt reduces financial flexibility, raises interest and covenant exposure, and limits the firm's ability to absorb clinical setbacks or invest organically without further dilutive or costly financing.
Cellectis SA News
CMVLF FAQ
What was Cellectis SA’s price range in the past 12 months?
Cellectis SA lowest stock price was $1.25 and its highest was $5.04 in the past 12 months.
What is Cellectis SA’s market cap?
Cellectis SA’s market cap is $294.19M.
When is Cellectis SA’s upcoming earnings report date?
Cellectis SA’s upcoming earnings report date is Apr 30, 2026 which is today.
How were Cellectis SA’s earnings last quarter?
Currently, no data Available
Is Cellectis SA overvalued?
According to Wall Street analysts Cellectis SA’s price is currently Overvalued.
Does Cellectis SA pay dividends?
Cellectis SA does not currently pay dividends.
What is Cellectis SA’s EPS estimate?
Cellectis SA’s EPS estimate is -0.26.
How many shares outstanding does Cellectis SA have?
Cellectis SA has 72,325,455 shares outstanding.
What happened to Cellectis SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Cellectis SA?
Currently, no hedge funds are holding shares in CMVLF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cellectis SA
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
CMVLF Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in advancing pivotal clinical trials and maintaining a strong financial position, with ongoing collaborations and upcoming strategic events. However, ongoing arbitration and a decrease in cash reserves posed challenges.View all CMVLF earnings summariesTechnical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
0.02% Other Institutional Investors
99.98% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---